These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27870480)

  • 1. Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects.
    Umemura K; Iwaki T; Kimura T; Ogawa C; Fukuda T; Taniguchi S; Horibe K; Goto H; Yoshimura K; Watanabe Y; Nitani C; Kikuta A
    Clin Pharmacol Drug Dev; 2016 Nov; 5(6):548-551. PubMed ID: 27870480
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacokinetics of defibrotide in uremic patients undergoing hemodialysis].
    Rossi R; Farma A; Maggi GC; Marelli A
    Minerva Med; 1991 Dec; 82(12):853-7. PubMed ID: 1780093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolytic effects of defibrotide in atherosclerotic patients.
    Patrassi GM; Sartori MT; Viero ML; Scapinello MP; Boeri G; Girolami A
    Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study on pharmacokinetics of radioactive labelled defibrotide after oral or intravenous administration in rats.
    Fisher J; Holland TK; Pescador R; Porta R; Ferro L
    Thromb Res; 1996 Jan; 81(1):55-63. PubMed ID: 8747520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption through the peritoneum of the macromolecular profibrinolytic drug defibrotide in the rabbit.
    Porta R; Calvani AB; Pescador R; Mantovani M; Prino G
    Semin Thromb Hemost; 1991 Oct; 17(4):404-6. PubMed ID: 1803509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tissue plasminogen activator inhibitor by defibrotide in atherosclerotic patients.
    Violi F; Ferro D; Alessandri C; Quintarelli C; Saliola M; Balsano F
    Semin Thromb Hemost; 1989 Apr; 15(2):226-9. PubMed ID: 2501872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
    Echart CL; Graziadio B; Somaini S; Ferro LI; Richardson PG; Fareed J; Iacobelli M
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):627-34. PubMed ID: 19809307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of defibrotide in patients with renal impairment.
    Tocchetti P; Tudone E; Marier JF; Marbury TC; Zomorodi K; Eller M
    Drug Des Devel Ther; 2016; 10():2631-41. PubMed ID: 27574402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-performance liquid chromatography determination of polydeoxyribonucleotides in plasma: its application to the determination of defibrotide's pharmacokinetics in the rabbit.
    Porta R; Moltrasio D; Pescador R; Lanzarotti E; Mantovani M; Prino G
    Anal Biochem; 1992 Jul; 204(1):143-6. PubMed ID: 1514679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of defibrotide in healthy volunteers.
    Noseda G; Fragiacomo C; Ferrari D
    Haemostasis; 1986; 16 Suppl 1():26-30. PubMed ID: 3754833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Defibrotide and of its profibrinolytic activity in the rabbit.
    Pescador R; Mantovani M; Prino G; Madonna M
    Thromb Res; 1983 Apr; 30(1):1-11. PubMed ID: 6687960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defibrotide: an overview of clinical pharmacology and early clinical studies.
    Cornelli U; Nazzari M
    Semin Thromb Hemost; 1988; 14 Suppl():64-70. PubMed ID: 3057638
    [No Abstract]   [Full Text] [Related]  

  • 13. Defibrotide therapy for thrombophlebitis--controlled clinical trial.
    Di Perri T; Vittoria A; Messa GL; Cappelli R
    Haemostasis; 1986; 16 Suppl 1():42-7. PubMed ID: 3754835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficient fibrinolytic response in patients with Raynaud's phenomenon and its correction with defibrotide.
    Cimminiello C; Milani M; Pietra A; Rossi F; Aloisio M; Nazzari M; Bonfardeci G
    Semin Thromb Hemost; 1991; 17 Suppl 1():106-11. PubMed ID: 2068563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolytic enhancement in diabetic microangiopathy with defibrotide.
    Belcaro G; Marelli C; Pomante P; Laurora G; Cesarone MR; Ricci A; Girardello R; Barsotti A
    Angiology; 1992 Oct; 43(10):793-800. PubMed ID: 1476266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a defibrotide-heparin combination on some measures of haemostasis in healthy volunteers.
    Pogliani EM; Salvatore M; Fowst C; Girardello R; Marelli C
    J Int Med Res; 1989; 17(1):36-40. PubMed ID: 2707475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
    Corbacioglu S; Richardson PG
    Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
    Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study.
    Laurora G; Ambrosoli L; Cesarone MR; De Sanctis MT; Incandela L; Marelli C; Belcaro G
    Panminerva Med; 1994 Jun; 36(2):83-6. PubMed ID: 7831064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide.
    Ulutin ON; Cizmeci G; Balkuv-Ulutin S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):177-80. PubMed ID: 2459016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.